Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

RELEASE OF ANGIOGENIC INHIBITORS FOR MACULAR EDEMA

Award Number: R43EY015581
ORGANIZATION: NATIONAL EYE INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/30/2004
PERIOD OF PERFORMANCE END DATE: 09/29/2005

Group Awards By:

View Award Description

RELEASE OF ANGIOGENIC INHIBITORS FOR MACULAR EDEMA - DESCRIPTION (provided by applicant) Increased vascular permeability or vascular leakage in the retina is an early and common feature of diabetic retinopathy and can result in diabetic macular edema. Vascular leakage is also responsible for cystoid macular edema (CME) secondary to cataract surgery, which is very common in diabetic patients. Overexpression of VEGF is a major causative factor leading to vascular leakage in diabetic retinopathy. Currently, there is no satisfactory treatment for macular edema, which remains a major cause of vision loss. Our recent studies have shown that several peptide angiogenic inhibitors, such as plasminogen kringle 5 (K5) and kallistatin, can reduce pathological vascular leakage in the retina. These peptides significantly decreased vascular leakage at doses much lower than that required for the inhibition of neovascularization. Furthermore, our preliminary data suggest that the K5-induced reduction of vascular leakage may be through blocking hypoxia-induced VEGF over-expression in the retina, while kallistatin reduces vascular leakage via blocking VEGF binding to its receptors. As diabetic macular edema is a multi-factorial and chronic disorder, we hypothesize that a sustained ocular delivery of a cocktail of multiple angiogenic inhibitors with different molecular targets may induce a long-term reduction of vascular leakage in diabetic retina. Our long-term goal is to develop a new treatment for CME and diabetic macular edema using peptide angiogenic inhibitors. In this Phase I project, we propose to prove two concepts: 1) the combination of two or more peptide angiogenic inhibitors with different molecular targets may have a synergistic effect on reduction of vascular leakage; 2) a sustained ocular delivery of angiogenic inhibitors may result in a long-term reduction of vascular leakage in the retina. We plan to use K5 and kallistatin as the first candidates for these studies, as they have displayed potent effects on vascular leakage when they were used alone, and they have different molecular mechanisms for their effects on vascular leakage. The synergistic effect on vascular leakage between K5 and kallistatin will be evaluated in a diabetic rat model. A sustained delivery system using slow-releasing peptide polymers will be developed. The pharmacokinetics of the peptides with different delivery routes will be compared. The long-term effect of the sustained delivery of K5 and kallistatin on vascular leakage will be evaluated in a diabetic animal model. This project is a necessary step in exploring the therapeutic and commercial potential of K5 and kallistatin as drugs for the treatment of diabetic macular edema. These studies will generate essential preclinical data for the development of a new treatment for diabetic macular edema using these peptides in Phase II. This new treatment will use natural human peptides and will be less invasive, compared to the current treatments. The slow releasing polymers and delivery techniques can be applied to other peptide drugs in the treatment of ocular disorders.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2004 ( Subtotal = $100,000 )
2004	2004	CHARLESSON LLP	POST OFFICE BOX 14103	OKLAHOMA CITY	OK	73113	OKLAHOMA	USA	Vision Research	000	1	9/27/2004	NEW	$100,000
														Subtotal = $100,000

Grand Total All Awards = $100,000

Top

All Categories

About

Search

Reports

Data Submission

Award Information

RELEASE OF ANGIOGENIC INHIBITORS FOR MACULAR EDEMA

Award Number: R43EY015581

ORGANIZATION: NATIONAL EYE INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/30/2004

PERIOD OF PERFORMANCE END DATE: 09/29/2005

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer